The Effectiveness of Idazoxan in Treating TRD

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
Sheba Medical Center
ClinicalTrials.gov Identifier:
NCT00294944
First received: February 19, 2006
Last updated: January 28, 2008
Last verified: January 2008
  Purpose

Assessing the effectiveness of Idazoxan as a treatment for depressive patients who did not respond to treatment with SSRI


Condition Intervention Phase
Major Depressive Disorder
Drug: Idazoxan
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind

Further study details as provided by Sheba Medical Center:

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • MDD patients
  • Did not respond to at least one treatment of 4-6 weeks of SSRI in adequate dose
  • In or out patients

Exclusion Criteria:

  • Psychotic symptoms
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00294944

Locations
Israel
Chaim Sheba Medical Center
Ramat-Gan, Israel, 52621
Sponsors and Collaborators
Sheba Medical Center
Investigators
Principal Investigator: Joseph Zohar, MD Sheba Medical Center
  More Information

No publications provided

Responsible Party: Prof. Joseph Zohar, Chaim Sheba Medical Center
ClinicalTrials.gov Identifier: NCT00294944     History of Changes
Other Study ID Numbers: SHEBA-05-3911-JZ-CTIL
Study First Received: February 19, 2006
Last Updated: January 28, 2008
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Depressive Disorder
Depression
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms
Idazoxan
Adrenergic alpha-2 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 30, 2014